Head to Head Comparison: 4D Molecular Therapeutics (FDMT) and Its Competitors – Defense World

4D Molecular Therapeutics (NASDAQ:FDMT Get Rating) is one of 263 publicly-traded companies in the Biological products, except diagnostic industry, but how does it compare to its competitors? We will compare 4D Molecular Therapeutics to similar companies based on the strength of its profitability, earnings, risk, valuation, institutional ownership, analyst recommendations and dividends.

Risk and Volatility

4D Molecular Therapeutics has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics competitors have a beta of 0.75, indicating that their average stock price is 25% less volatile than the S&P 500.

This is a summary of current ratings and recommmendations for 4D Molecular Therapeutics and its competitors, as reported by MarketBeat.

4D Molecular Therapeutics currently has a consensus target price of $26.00, suggesting a potential upside of 271.43%. As a group, Biological products, except diagnostic companies have a potential upside of 93.18%. Given 4D Molecular Therapeutics stronger consensus rating and higher probable upside, equities research analysts plainly believe 4D Molecular Therapeutics is more favorable than its competitors.

Earnings and Valuation

This table compares 4D Molecular Therapeutics and its competitors revenue, earnings per share and valuation.

4D Molecular Therapeutics competitors have higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares 4D Molecular Therapeutics and its competitors net margins, return on equity and return on assets.

Insider and Institutional Ownership

76.6% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 53.4% of shares of all Biological products, except diagnostic companies are held by institutional investors. 11.2% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 16.3% of shares of all Biological products, except diagnostic companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

4D Molecular Therapeutics beats its competitors on 8 of the 13 factors compared.

4D Molecular Therapeutics Company Profile (Get Rating)

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

See the article here:
Head to Head Comparison: 4D Molecular Therapeutics (FDMT) and Its Competitors - Defense World